Current Clinical Trials

Current Clinical Trials

Clinical trials are experiments that test whether a new compound is both safe for human use and effective for treatment of the disease it is being evaluated for. For individuals with a neurodgenerative form of dementia (any form) there are curently no effective disease-modifying treatments, and even existing symptomatic therapies are very weak. Without MANY volunteers who are willing to take the risk of exposure to an incompletely-tested agent, we will never achieve the aim of slowing, stopping, or reversing the effects of these disease.

If you are eligible to participate, please consider volunteering.

Phase I Study of BMS-241027

For individuals with mild Alzheimer's disease and Mini Mental State score of 20-26.

The purpose of this study is to test the safety and tolerability of BMS-241027, compared to placebo (inactive substance) in subjects with mild Alzheimer’s disease. This is a phase 1 (first in humans) study of a compound that may help to stabilize components of tau protein- a protein that becomes deformed and unusable in the neurons of people with Alzheimer’s disease. If this study is successful, it will point the way toward larger-scale trials to assess the efficacy of this compound at slowing or halting disease progression.

Phase 2 Study of BAN2401

For individuals with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and Mini Mental State score 22-30.

The purpose of this study is to evaluate the efficacy of BAN-2401 compared to placebo by establishing the most effective dose on a measure of cognitive function at 12 and 18 months of treatment. The study will also measure the effects of different doses of the drug on hippocampal atrophy (as measured by MRI) and brain amyloid (as measured by Amyvid PET). This is a phase 2 study of a monoclonal antibody targeted against soluble amyloid fibrils (as opposed to deposits of insoluble brain amyloid contained in plaques). If this study is successful, it would lead to a large-scale phase 3 study to evaluate the efficacy of whichever dose proved to be most effective in this phase 2 trial.

Healthy Seniors for Brain Imaging Studies

We are always looking for participants over age 70 to serve as comparison groups for our Alzheimer’s patient sample. You must be able to get an MRI scan (no claustrophobia, no pacemaker or cardiac stent, no metal in the head, neck or eyes). The purpose of these studies is to improve understanding of how changes in the brains of those with Alzheimer’s disease and those with mild memory and thinking impairments are related to behavioral changes.

The study involves two components, and takes place on campus, in the Clinical Center/Radiology complex on Service Road. First, you will be asked to answer questions that assess thinking abilities. Participants without cognitive impairment will also be asked to identify themselves in photographs and will partake in measurement of behavioral responses to various levels of minor discomfort (forearm pressure). This component of the study takes 20-40 minutes.

The second part of the study lasts for about an hour and involves an MRI scan of the brain (NO radiation or injections are involved). During part of the scanning, participants with no memory or thinking impairments will view pictures of faces followed by laying in the scanner at rest. Those participants with mild memory and thinking impairments will only lie in the scanner at rest. After scanning, you will also have a blood draw for genetic testing (a single vial). You will be paid $20 for completing the study.

If you are interested in participating and are a senior with no memory impairment, please contact Paul Beach at (269) 251-0027 or pabeach1@gmail.com. If you believe you may have some memory or other thinking impairments and wish to participate, please contact Ashley Hannah at (216) 370-1900 or hannahas@msu.edu.

For each study, please click here to obtain more information about eligibility criteria, study logistics and scheduling an appointment for screening.

Developed by DECS | Contact Information | Privacy Statement | Site Accessibility

MSU is an affirmative action, equal opportunity employer

© Michigan State University Board of Trustees, East Lansing, MI 48824